Worth reading
34Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
187000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of the First Series of Stock Acquisition Rights issued through a third-party allotment with an exercise price adjustment clause
Who receives how much
Number of shares delivered during the month: 187,000 shares (187,000 new shares; 0 treasury shares transferred)
EVO FUND (issued on 24 February 2026)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
187,000 shares delivered during the month; exercise ratio subject to the exercise restrictions: 3.1%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Subject to an exercise price adjustment clause. The exercise price during the target month ranged from ¥242 to ¥287 (no exercise on 30 April; exercise price: ¥246)
Number of Stock Acquisition Rights
Total issued: 9,860 rights; exercised during the target month: 1,870 rights; unexercised as of the end of April 2026: 6,950 rights (695,000 shares)
Procedures under the Corporate Code of Conduct
Disclosure of compliance with the exercise restrictions under Article 434 of the Listing Regulations. The exercise ratio subject to the exercise restrictions was 3.1%.
Most recent equity financing
Issued on 24 February 2026: First Series of Stock Acquisition Rights with an exercise price adjustment clause, allocated to EVO FUND; total issued: 9,860 rights
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the First Series of Stock Acquisition Rights issued through a third-party allotment with an exercise price adjustment clause |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 187,000 shares (187,000 new shares; 0 treasury shares transferred) |
| Intended allottee | EVO FUND (issued on 24 February 2026) |
| Dilution Rate | 187,000 shares delivered during the month; exercise ratio subject to the exercise restrictions: 3.1% |
| Total number of issued shares | As of the end of the month preceding the target month: 7,557,350 shares → Not disclosed |
| Exercise price | Subject to an exercise price adjustment clause. The exercise price during the target month ranged from ¥242 to ¥287 (no exercise on 30 April; exercise price: ¥246) |
| Number of Stock Acquisition Rights | Total issued: 9,860 rights; exercised during the target month: 1,870 rights; unexercised as of the end of April 2026: 6,950 rights (695,000 shares) |
| Procedures under the Corporate Code of Conduct | Disclosure of compliance with the exercise restrictions under Article 434 of the Listing Regulations. The exercise ratio subject to the exercise restrictions was 3.1%. |
| Most recent equity financing | Issued on 24 February 2026: First Series of Stock Acquisition Rights with an exercise price adjustment clause, allocated to EVO FUND; total issued: 9,860 rights |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of these Stock Acquisition Rights in April 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.